Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

MERCAPTOPURINE for T-cell type acute leukaemia: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 251 adverse event reports in the FDA FAERS database where MERCAPTOPURINE was used for T-cell type acute leukaemia.

Most Reported Side Effects for MERCAPTOPURINE

Side Effect Reports % Deaths Hosp.
Febrile neutropenia 1,853 16.1% 97 1,479
Off label use 893 7.8% 95 290
Pyrexia 855 7.4% 45 759
Drug ineffective 721 6.3% 75 230
Vomiting 488 4.3% 38 373
Neutropenia 485 4.2% 41 335
Nausea 418 3.6% 14 304
Pneumonia 394 3.4% 160 202
Pancytopenia 392 3.4% 66 258
Sepsis 389 3.4% 96 268
Abdominal pain 367 3.2% 14 223
Bacterial infection 365 3.2% 267 61
Anaemia 357 3.1% 17 265
Diarrhoea 352 3.1% 22 222
Febrile bone marrow aplasia 308 2.7% 8 302

Other Indications for MERCAPTOPURINE

Acute lymphocytic leukaemia (4,815) Product used for unknown indication (1,136) Crohn's disease (705) Colitis ulcerative (512) B precursor type acute leukaemia (484) B-cell type acute leukaemia (308) Chemotherapy (199) Precursor t-lymphoblastic lymphoma/leukaemia (186) Acute promyelocytic leukaemia (175) Non-hodgkin's lymphoma (143)

Other Drugs Used for T-cell type acute leukaemia

VINCRISTINE (763) METHOTREXATE (739) CYTARABINE (520) DEXAMETHASONE (452) CYCLOPHOSPHAMIDE (436) DAUNORUBICIN (367) DOXORUBICIN (306) PEGASPARGASE (297) ASPARAGINASE (282) NELARABINE (238)

Related Pages

MERCAPTOPURINE Full Profile All T-cell type acute leukaemia Drugs MERCAPTOPURINE Demographics MERCAPTOPURINE Timeline